{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:53:04Z","timestamp":1784130784013,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ekir.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:12:25Z","timestamp":1744171945000},"page":"1907-1916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-3745","authenticated-orcid":false,"given":"Patrick","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ragy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrityunjay","family":"Hiremath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-2832","authenticated-orcid":false,"given":"Anirudh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-3649","authenticated-orcid":false,"given":"Arif","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga","family":"Anil K Kanigicherla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.04.005_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.04.005_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.005_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ki.1988.56","article-title":"Idiopathic membranous nephropathy: the natural history of untreated patients","volume":"33","author":"Donadio","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.005_bib5","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/ndt\/gfv435","article-title":"Long-term outcomes of persistent disease and relapse in primary membranous nephropathy","volume":"31","author":"Kanigicherla","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ekir.2025.04.005_bib6","first-page":"61","article-title":"The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults","volume":"22","author":"Davison","year":"1984","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib7","first-page":"139","article-title":"KDIGO 2012 Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.ekir.2025.04.005_bib8","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.005_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ekir.2023.05.019","article-title":"PLA2R antibody does not outperform conventional clinical markers in predicting outcomes in membranous nephropathy","volume":"8","author":"Ragy","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.04.005_bib10","author":"Therneau"},{"key":"10.1016\/j.ekir.2025.04.005_bib11","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.ekir.2025.04.005_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.04.005_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000518609","article-title":"Immunosuppressive therapy in primary membranous nephropathy with compromised renal function","volume":"146","author":"Ramachandran","year":"2022","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2025.04.005_bib15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae179","article-title":"Prospective study on the effect of rituximab on kidney function in membranous nephropathy","volume":"17","author":"Kanigicherla","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.04.005_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.04.005_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1523-1755.1999.00598.x","article-title":"Prediction in idiopathic membranous nephropathy","volume":"56","author":"Marx","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.005_bib19","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2215\/CJN.00670112","article-title":"Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy","volume":"7","author":"Brand JAJG","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.005_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12967-019-1792-8","article-title":"New risk score for predicting progression of membranous nephropathy","volume":"17","author":"Xiaofan","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.ekir.2025.04.005_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11255-021-02859-x","article-title":"Nomogram to predict the progression of patients with primary membranous nephropathy and nephrotic syndrome","volume":"54","author":"Liu","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1681\/ASN.2004040287","article-title":"Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study","volume":"16","author":"Branten","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.005_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1002117","article-title":"Rituximab in patients with membranous nephropathy and kidney insufficiency","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.04.005_bib25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.kint.2018.12.018","article-title":"Health-related quality of life in glomerular disease","volume":"95","author":"Canetta","year":"2019","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ekir.2025.04.005_bib26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ekir.2021.04.002","article-title":"Anti-PLA2R1 antibodies as prognostic biomarker in membranous nephropathy","volume":"6","author":"Logt","year":"2021","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925002062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925002062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:25:54Z","timestamp":1752765954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925002062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2468024925002062"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.04.005","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}